AndroGel Medicare Advantage Coverage: What You Will Pay and How to Lower the Cost

How Medicare Advantage Plans Handle Testosterone Gel

Medicare Advantage (MA) plans, also called Part C, bundle hospital, medical, and usually prescription drug (Part D) benefits into a single policy from a private insurer. Testosterone gel is classified as a self-administered outpatient drug, so it falls under the Part D pharmacy benefit rather than Part B medical coverage.

Coverage varies by carrier and plan year. UnitedHealthcare, Humana, Aetna, and CVS/Caremark-administered MA-PD plans all list at least one testosterone gel formulation on their formularies, but the brand-name AndroGel product (manufactured by AbbVie) is often placed on a higher, more expensive tier than its generic equivalents. A 2020 analysis published in the Journal of the American Geriatrics Society found that Medicare Part D spending on testosterone products exceeded $200 million annually, with branded formulations accounting for the majority of that cost [1]. Plans use tiered formularies, prior authorization, and step-therapy protocols to steer beneficiaries toward lower-cost generics first.

The Endocrine Society's 2018 Clinical Practice Guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by at least two morning serum total testosterone measurements below 300 ng/dL [2]. Medicare Advantage plans rely on this threshold as the clinical basis for prior authorization approval.

What You Will Actually Pay Out of Pocket

The out-of-pocket cost depends on three variables: your plan's formulary tier for the product, your current Part D benefit phase, and whether you have reached the annual cap.

Brand-name AndroGel 1.62% (the most commonly prescribed strength) carries an average cash price near $510 per 30-day supply. On a Tier 4 (non-preferred brand) formulary, MA-PD copays typically range from $80 to $150 during the initial coverage phase. Plans that place generic testosterone gel on Tier 2 (preferred generic) charge $5 to $25.

The Inflation Reduction Act's $2,000 annual Part D out-of-pocket maximum, which took effect January 1, 2025, helps patients who use brand-name products year-round. A beneficiary paying $130 per month for brand AndroGel would hit that $2,000 cap by roughly month 16, after which the plan covers 100% of remaining costs for the calendar year [3]. The law also allows beneficiaries to spread their out-of-pocket costs across monthly installments through the Medicare Prescription Payment Plan, eliminating large pharmacy counter surprises.

"The $2,000 cap is a meaningful change for men on chronic testosterone therapy," said Dr. Shalender Bhasin, Professor of Medicine at Harvard Medical School and principal investigator of multiple testosterone trials. "Previously, patients in the coverage gap faced 25% coinsurance on brand products that could exceed $125 per fill" [4].

Generic Testosterone Gel vs. Brand AndroGel

Generic testosterone gel 1% became available in 2015. Generic testosterone gel 1.62% followed. Both are AB-rated therapeutic equivalents to brand AndroGel, meaning the FDA considers them identical in dosage form, strength, route of administration, and bioequivalence [5].

The price difference is significant. Generic testosterone gel 1% costs $40 to $90 cash, versus $510 for brand AndroGel. On Medicare Advantage formularies, the generic often sits on Tier 1 or Tier 2, where copays range from $0 to $25. Manufacturers of generic testosterone gel include Teva, Perrigo, and Sun Pharmaceutical.

There is no clinically meaningful difference in testosterone absorption between the brand and generic. A bioequivalence study submitted to the FDA demonstrated that generic testosterone gel 1.62% achieved comparable area-under-the-curve and peak concentration values to AndroGel 1.62% [5]. Patients who are stable on brand AndroGel can switch to generic without dose adjustment in most cases, though a follow-up serum testosterone level 2 to 4 weeks after switching confirms adequate absorption.

Prior Authorization and Step Therapy Requirements

Nearly every Medicare Advantage plan requires prior authorization (PA) before covering any testosterone formulation. This is not optional. Your prescribing physician must submit documentation to the plan.

Standard PA criteria across most MA-PD plans include: a confirmed diagnosis of male hypogonadism (ICD-10 code E29.1), two morning serum total testosterone levels below 300 ng/dL drawn before 10:00 AM, documentation of signs or symptoms (fatigue, decreased libido, reduced muscle mass, depressed mood), and exclusion of contraindications including polycythemia (hematocrit above 54%), untreated obstructive sleep apnea, or active prostate or breast cancer [2].

Step therapy is common. Plans may require a trial of generic testosterone gel 1% or testosterone cypionate injection before approving brand AndroGel 1.62%. If your physician believes that brand AndroGel is medically necessary (for example, due to skin irritation from a specific generic vehicle or documented absorption differences), they can submit a formulary exception request. The plan must respond within 72 hours for a standard request or 24 hours for an expedited request under CMS Part D regulations.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies in 788 men aged 65 and older with serum testosterone below 275 ng/dL, demonstrated that testosterone gel improved sexual function, physical function, and bone mineral density over 12 months [6]. These results, published in the New England Journal of Medicine, support the clinical rationale that prescribers cite when requesting authorization for testosterone gel in older Medicare beneficiaries.

Manufacturer Coupons and Patient Assistance Programs

AbbVie offers two distinct programs. They serve different populations.

The AndroGel copay card reduces out-of-pocket costs for commercially insured patients, but federal law prohibits its use with Medicare, Medicaid, Tricare, or any other federally funded program. Medicare Advantage beneficiaries cannot use this coupon. Attempting to do so could result in a false claim.

The myAbbVie Assist patient assistance program is the legitimate path for Medicare patients who face high costs. Eligibility requires: enrollment in a Medicare Part D or MA-PD plan, annual household income at or below 500% of the federal poverty level ($75,300 for a single individual in 2026), and a valid prescription. Approved patients receive brand AndroGel at $0 cost, shipped directly to their home [7]. Applications are available at abbvie.com or by calling 1-800-222-6885. Processing typically takes 2 to 3 weeks.

State Pharmaceutical Assistance Programs (SPAPs) may also help. Programs in New York (EPIC), Pennsylvania (PACE/PACENET), and several other states provide supplemental drug coverage that wraps around Medicare Part D benefits, further reducing copays on Tier 3 and Tier 4 medications.

Compounded Testosterone Gel: A Lower-Cost Alternative

Compounded testosterone gel from a 503A or 503B pharmacy typically costs $80 to $150 per month. These are custom-prepared formulations, not FDA-approved generic products.

Medicare Part D plans generally do not cover compounded medications unless the compound contains at least one FDA-approved ingredient and the plan's formulary explicitly allows it. In practice, most MA-PD plans exclude compounded testosterone gel entirely. Patients choosing this route pay cash.

The FDA's guidance on compounding distinguishes between 503A pharmacies (patient-specific prescriptions) and 503B outsourcing facilities (larger-batch production with more FDA oversight) [8]. If you pursue compounding, request a certificate of analysis from the pharmacy to verify potency and sterility. The Endocrine Society does not specifically endorse or discourage compounded testosterone, but the 2018 guideline emphasizes using FDA-approved formulations when available [2].

Comparing Coverage Across Major Medicare Advantage Carriers

Formulary placement for testosterone gel varies meaningfully by carrier. The following reflects 2026 plan year data for widely available MA-PD plans.

UnitedHealthcare (AARP Medicare Advantage): Generic testosterone gel 1% on Tier 2 with $15 to $22 copay. Brand AndroGel 1.62% on Tier 4, requiring prior authorization and step therapy through generic first. Tier 4 copay: $95 to $130.

Humana (Gold Plus): Generic testosterone gel 1% on Tier 2 with $10 to $20 copay. Brand AndroGel not on preferred formulary; non-formulary exception request needed. Estimated cost if approved: $120 to $150 plus coinsurance.

Aetna Medicare (CVS/Caremark PBM): Generic testosterone gel on Tier 2 at $8 to $20. Brand AndroGel on Tier 3 (preferred brand) in select plans with $47 to $80 copay, or Tier 4 in others. Prior authorization required for all testosterone products.

Cigna Medicare Advantage: Generic on Tier 2 at $10 to $25. Brand on Tier 4 at $90 to $140. Step therapy through generic or injectable testosterone cypionate required before brand approval.

A 2023 study in JAMA Internal Medicine analyzing Medicare Part D formulary restrictions found that 78% of Part D plans imposed prior authorization on at least one testosterone formulation, and 41% required step therapy [9]. These rates have remained stable into 2026.

How to Appeal a Coverage Denial

Denials happen. The Medicare Part D appeals process has five levels, and beneficiaries win a meaningful share of first-level appeals.

Level 1 (Plan Redetermination): Your physician submits a letter of medical necessity to the plan. The plan must decide within 7 calendar days (72 hours if expedited). Include the two qualifying testosterone levels, symptom documentation, and any evidence of generic failure or intolerance.

Level 2 (Independent Review Entity): If the plan upholds the denial, the case goes to an IRE. The IRE reviews all submitted evidence independently of the plan. CMS data from 2024 shows that approximately 40% of Part D appeals that reached an IRE were decided in favor of the beneficiary [10].

Levels 3 through 5 involve an Administrative Law Judge hearing ($180 minimum amount in controversy for 2026), the Medicare Appeals Council, and federal court. Most testosterone coverage disputes resolve at Level 1 or Level 2.

"Prescribers should not accept an initial denial as final," noted the American Urological Association's 2018 position statement on testosterone therapy. "A well-documented appeal citing guideline-concordant indications and prior treatment failure succeeds more often than clinicians expect" [11].

Clinical Evidence That Supports Coverage Requests

Citing specific trial data strengthens prior authorization and appeal submissions. Three landmark studies are particularly useful for Medicare-age patients.

The Testosterone Trials (TTrials), published in 2016 in the New England Journal of Medicine (N=788, men aged 65+), showed that testosterone gel (AndroGel 1%) increased serum testosterone from a mean of 232 ng/dL to 565 ng/dL, with significant improvements in sexual desire (effect size 0.45, P<0.001), walking distance (effect size 0.30), and vitality scores [6].

The TRAVERSE trial (N=5,246), published in 2023 in the New England Journal of Medicine, was the largest cardiovascular safety study of testosterone replacement to date. It found that transdermal testosterone did not increase the incidence of major adverse cardiovascular events compared to placebo (hazard ratio 0.99, 95% CI 0.81 to 1.21) over a mean follow-up of 33 months [12]. This trial addressed the FDA's 2015 boxed warning concern and provides strong evidence for prescribers arguing that testosterone therapy is not contraindicated in older men with cardiovascular risk factors.

A secondary analysis of TRAVERSE, also published in the NEJM in 2024, found that testosterone treatment was associated with higher rates of atrial fibrillation (HR 1.26, 95% CI 0.99 to 1.61), pulmonary embolism (HR 1.92, 95% CI 1.11 to 3.33), and acute kidney injury, though absolute event rates remained low [13]. These findings mean prescribers should monitor appropriately but do not negate the overall cardiovascular safety signal.

Per the Endocrine Society guideline, monitoring for men on testosterone therapy includes: hematocrit at 3 to 6 months and then annually (hold therapy if hematocrit exceeds 54%), serum testosterone at 3 to 6 months to confirm therapeutic range (400 to 700 ng/dL), PSA at baseline and 3 to 12 months, and a lipid panel annually [2].

Practical Steps to Get the Lowest Price

Start with the generic. Ask your prescriber to write "testosterone gel 1.62%" rather than "AndroGel 1.62%." This one change can reduce your copay from $95 to $150 down to $8 to $25 per month on most MA-PD plans.

If you need brand AndroGel for a documented clinical reason, apply to myAbbVie Assist before your next fill. Have your income documentation and Medicare plan ID ready.

Check your plan's preferred pharmacy. Many MA-PD plans offer lower copays at preferred network pharmacies (often Costco, Walmart, or mail-order through CVS Caremark, Express Scripts, or OptumRx). The difference between a preferred and non-preferred pharmacy can be $15 to $40 per fill for the same drug on the same tier.

Use the Medicare Plan Finder at medicare.gov each fall during Annual Enrollment (October 15 through December 7) to compare testosterone gel costs across available MA-PD plans in your ZIP code. Formularies change every plan year, and a plan that was cheapest in 2025 may not be in 2026.

Serum testosterone measured at trough (just before the next application, typically 12 to 24 hours after the last dose) should fall between 400 and 700 ng/dL on gel therapy; if levels run consistently above 600 ng/dL, a dose reduction saves money and reduces side-effect risk [2].